167 related articles for article (PubMed ID: 34327425)
1. The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic review.
Chen H; Zhou Y; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Mar; 8():100097. PubMed ID: 34327425
[TBL] [Abstract][Full Text] [Related]
2. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.
Zhong Q; Tao Y; Chen H; Zhou Y; Huang L; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Jun; 11():100151. PubMed ID: 34327360
[TBL] [Abstract][Full Text] [Related]
3. Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021.
Bo C; Wang T; Hou C; Han J; Chen L; Zhang H; Wang L; Li H
CNS Neurosci Ther; 2022 Aug; 28(8):1229-1239. PubMed ID: 35642775
[TBL] [Abstract][Full Text] [Related]
4. The landscape of investigator-initiated oncology trials conducted in mainland China during the past decade (2010-2019).
Cao Y; Ye LM; Fan Z; Yang W; Chen LY; Mei Y; He DY; Mo WJ
Cancer Innov; 2023 Feb; 2(1):79-90. PubMed ID: 38090374
[TBL] [Abstract][Full Text] [Related]
5. Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011-2020).
Chen C; Lou N; Zheng X; Wang S; Chen H; Han X
Front Med (Lausanne); 2021; 8():777698. PubMed ID: 34977078
[No Abstract] [Full Text] [Related]
6. Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023.
Jia W; Yu H; Song L; Wang J; Niu S; Zang G; Liang M; Liu J; Na R
Front Med (Lausanne); 2023; 10():1239351. PubMed ID: 38034540
[TBL] [Abstract][Full Text] [Related]
7. The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009-2021.
Li C; Hao J; Zheng Y; Wang C; Yang J; Wang W; Zhang K; Shao C; Hui W; Wang J; Li W; Tang YD
Diabetol Metab Syndr; 2023 Apr; 15(1):66. PubMed ID: 37005689
[TBL] [Abstract][Full Text] [Related]
8. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
9. Pediatric Clinical Trials in Mainland China Over the Past Decade (From 2009 to 2020).
Wu WW; Ji X; Wang H; Chen F; Ding Q; Zhang GD; Li M; Wang SS; Ni MM; Liu QQ; Xu J; Wang Q
Front Med (Lausanne); 2021; 8():745676. PubMed ID: 34671625
[TBL] [Abstract][Full Text] [Related]
10. Current clinical trials on breast cancer in China: A systematic literature review.
Fan Y; Xu B
Cancer; 2020 Aug; 126 Suppl 16():3811-3818. PubMed ID: 32710659
[TBL] [Abstract][Full Text] [Related]
11. Recent landscape and trends for industry-sponsored pediatric clinical trials in China from 2013 to 2022.
Liu C; Liu Y; Ou L; Qi Y; Zhang J
Pediatr Investig; 2024 Mar; 8(1):12-20. PubMed ID: 38516137
[TBL] [Abstract][Full Text] [Related]
12. Biologics for Non-Cancer Dermatological Diseases: Analysis on China's Clinical Trial Registration Trend From 2016 to 2020.
Zhu B; Liu Y; Li J; Ni Q; Yin Z; Zhu J; Chen K; Yang X
Front Pharmacol; 2022; 13():817065. PubMed ID: 35529441
[No Abstract] [Full Text] [Related]
13. Chinese Clinical Trial Registry 13-year data collection and analysis: geographic distribution, financial support, research phase, duration, and disease categories.
Fan R; Zheng Y; Zhou R; Beeraka NM; Sukocheva OA; Zhao R; Li S; Zhao X; Liu C; He S; Mahesh PA; Gurupadayya BM; Nikolenko VN; Zhao D; Liu J
Front Med (Lausanne); 2023; 10():1203346. PubMed ID: 37901406
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
[TBL] [Abstract][Full Text] [Related]
15. Differences in Investigator-Initiated Trials between Japan and Other Countries: Analyses of Clinical Trials Sponsored by Academia and Government in the ClinicalTrials.gov Registry and in the Three Japanese Registries.
Ito T
PLoS One; 2016; 11(2):e0148455. PubMed ID: 26848574
[TBL] [Abstract][Full Text] [Related]
16. Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009-2022.
Li C; Hao J; Wang C; Yang J; Zheng Y; Zhang K; Hui W; Meng X; Gao J; Li W; Tang YD
Drug Des Devel Ther; 2023; 17():2315-2324. PubMed ID: 37559911
[TBL] [Abstract][Full Text] [Related]
17. Investigator initiated trials versus industry sponsored trials - translation of randomized controlled trials into clinical practice (IMPACT).
Blümle A; Wollmann K; Bischoff K; Kapp P; Lohner S; Nury E; Nitschke K; Zähringer J; Rücker G; Schumacher M
BMC Med Res Methodol; 2021 Aug; 21(1):182. PubMed ID: 34465296
[TBL] [Abstract][Full Text] [Related]
18. Characteristic analysis of clinical trials for new traditional Chinese medicines in mainland China from 2013 to 2021.
Zhou Y; Yang J; He Y; Lv Y; Wang C; Deng H; Huang J
Front Med (Lausanne); 2022; 9():1008683. PubMed ID: 36330068
[TBL] [Abstract][Full Text] [Related]
19. Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010-2019.
Liu X; Wu S; Sun J; Ni S; Lu L; Hu W; Wei H; Zou Y; Li T; Li J; Mijiti B; Fang P; Zhao L; Zhou H; Xing X; Niu H; Cao Y
Pharmacol Res Perspect; 2021 Apr; 9(2):e00729. PubMed ID: 33660404
[TBL] [Abstract][Full Text] [Related]
20. Trend of drug clinical trials in mainland China from 2009 to 2020.
Cao Y; Liao L; Liu X; Zheng Q; Xu Z; Niu H
Curr Med Res Opin; 2022 Sep; 38(9):1499-1507. PubMed ID: 35855662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
